168 related articles for article (PubMed ID: 31804856)
21. Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.
Hwang TJ; LaMattina JL
JAMA Oncol; 2016 Sep; 2(9):1125-6. PubMed ID: 27388928
[No Abstract] [Full Text] [Related]
22. The Problem of Cancer Drugs Costs: A Payer Perspective.
Newcomer LN
Cancer J; 2020; 26(4):287-291. PubMed ID: 32732670
[TBL] [Abstract][Full Text] [Related]
23. Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care.
Malin JL
J Clin Oncol; 2020 Feb; 38(4):367-371. PubMed ID: 31804871
[No Abstract] [Full Text] [Related]
24. US gets lower return on its cancer drug spending, study finds.
McCarthy M
BMJ; 2016 May; 353():i2494. PubMed ID: 27142646
[No Abstract] [Full Text] [Related]
25. US hospitals object to changes in Genentech drug distribution.
Furlow B
Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
[No Abstract] [Full Text] [Related]
26. Putting a price on hope.
Goozner M
J Natl Cancer Inst; 2012 Sep; 104(17):1274-5. PubMed ID: 22914787
[No Abstract] [Full Text] [Related]
27. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
28. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
29. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
30. Seeking value as cancer drug costs soar.
Bender E
Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
[TBL] [Abstract][Full Text] [Related]
31. Empower physicians to fight financial toxicity with biosimilars.
Oubre K
Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
[No Abstract] [Full Text] [Related]
32. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014.
Dusetzina SB
JAMA Oncol; 2016 Jul; 2(7):960-1. PubMed ID: 27123993
[No Abstract] [Full Text] [Related]
33. Chemotherapy treatment options and policies.
Breshears Wheeler J; Hanson K
NCSL Legisbrief; 2012 May; 20(19):1-2. PubMed ID: 22666895
[No Abstract] [Full Text] [Related]
34. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
Serritella AV; Strohbehn GW; Goldstein DA; Lichter AS; Ratain MJ
Clin Pharmacol Ther; 2020 Sep; 108(3):487-493. PubMed ID: 32298471
[TBL] [Abstract][Full Text] [Related]
35. "It's the economy, stupid": strategies for improved cost containment in cancer treatment.
Sleijfer S
Clin Pharmacol Ther; 2014 Apr; 95(4):365-7. PubMed ID: 24646487
[TBL] [Abstract][Full Text] [Related]
36. News feature: Costly US anticancer drugs pose problems for doctors and patients.
Charatan F
BMJ; 2008 Jul; 337(7662):a778. PubMed ID: 18625596
[TBL] [Abstract][Full Text] [Related]
37. [Cost/benefit analysis of cancer drugs].
Jordan B
Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
[TBL] [Abstract][Full Text] [Related]
38. Specialty medications: traditional and novel tools can address rising spending on these costly drugs.
Lotvin AM; Shrank WH; Singh SC; Falit BP; Brennan TA
Health Aff (Millwood); 2014 Oct; 33(10):1736-44. PubMed ID: 25288417
[TBL] [Abstract][Full Text] [Related]
39. How to Reduce Prescription Drug Prices: First, Do No Harm.
Atlas S
Mo Med; 2020; 117(1):14-15. PubMed ID: 32158034
[No Abstract] [Full Text] [Related]
40. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
